Feasibility study on treatment of switching to nilotinib after first-line imatinib in the chronic phase of chronic myeloid leukemia

Publication date: Available online 9 December 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yilin Chen, Hua Yin, Lifeng Chen, Yingyuan Xiong, Li Meng, Jingming Guo, Haiyan Wang, Weiming LiAbstractTo investigate the real-life choice of first-line treatment in the chronic phase of chronic myeloid leukemia (CML-CP) and the feasibility of switching to nilotinib treatment strategy after first-line imatinib. We went through retrospective analysis of the efficacy and safety of imatinib versus nilotinib for first-line for CML-CP patients, and comparative analysis of the efficacy of sustained imatinib versus switching to nilotinib for CML-CP patients with warning or failure response or intolerant to imatinib. We also comparatively analyzed the efficacy between first-line nilotinib and first-line imatinib after standardized management according to the ELN recommendations. A total of 344 patients were included in the study. The proportion of achieving complete cytogenetic response (CCyR), major molecular response (MMR), molecular response 4.0 (MR4.0) was higher for first-line nilotinib than in first-line imatinib by 0-24, and 0-36 months (P < 0.05). A total of 174 patients did not achieve the optimal response to first-line imatinib, patients switching to nilotinib achieved a greater proportion of CCyR, MMR and MR4.0 than those who sustaining imatinib at 12months subsequent treatment (P < 0.005). There was no difference in the proportion of achieving CCyR, MMR and ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research